Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Vitamin-D Supplementation: Impact on Severe Pneumonia Among Under-five Children (Vitamin-D)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02185196
Recruitment Status : Recruiting
First Posted : July 9, 2014
Last Update Posted : March 5, 2019
Sponsor:
Collaborator:
Centers for Disease Control and Prevention
Information provided by (Responsible Party):
International Centre for Diarrhoeal Disease Research, Bangladesh

Brief Summary:

Background:

  • Burden: Pneumonia is the leading cause of morbidity and mortality in under-five children, particularly in developing countries.
  • Knowledge gap: Although many studies have reported an association between vitamin D deficiency and pneumonia, there is lack in information on its therapeutic impact, i.e. the impact of vitamin D supplementation in the management of childhood pneumonia.
  • Relevance: Vitamin D plays an important role in modulating the innate immune response against infections. We, therefore, propose to conduct this study to assess the impact of vitamin D supplementation, in addition to standard antibiotic and supportive therapy, on the outcome of severe childhood pneumonia.

Hypothesis: The investigators hypothesise that in the management of hospitalized severe pneumonia in under-five children, vitamin D3 supplementation, as an adjunct to the standard antibiotic and other supportive therapy, will hasten recover from severe pneumonia and may thereby shorten duration of severe pneumonia and also reduce the risk of new episode of pneumonia.

Objectives: The objective of the investigators study is to assess the clinical benefit of oral supplementation of vitamin D3, in addition to standard antibiotic and other supportive therapy, to hospitalised, under-five children with severe pneumonia.

Methods: This would be a randomised, double blind, controlled clinical trial (RCT). Children of either sex, aged 3-59 months, attending the Dhaka Hospital of icddr,b, with clinically diagnosed severe pneumonia will comprise the study population. Eligible children will be allotted a sequential study number, which will have been previously assigned to vitamin D or placebo in accordance with the randomisation. The study staff and mothers/ caregivers of the children will be blinded as to whether vitamin D3 or placebo has been added to their child's diet. Infants aged 3-5 months will receive breast milk and/or infant formula, and those 6 months or older will receive "Milk Suji" as a complementary food. Vitamin D3 supplementation will be given on five consecutive days, from the day of enrolment in addition to standard antibiotic and other supportive therapy.

Outcome measures/variables:

Primary outcome measure will be time to resolution of severe pneumonia.

Secondary outcome measures will be duration of hospitalization, fever, tachypnoea, chest in drawing, hypoxia, lethargy and inability to feed during hospital stay and as well as new episode of pneumonia after discharge.


Condition or disease Intervention/treatment Phase
Pneumonia Drug: Vitamin D3 Drug: Placebo Phase 1

Detailed Description:

Hypothesis to be tested:

In a hypothesis testing research proposal, briefly mention the hypothesis to be tested and provide the scientific basis of the hypothesis, critically examining the observations leading to the formulation of the hypothesis.

Does this research proposal involve testing of hypothesis: 0 No 1 Yes (describe below)

The investigators hypothesise that supplementation of vitamin D3 (Cholecalciferol), in addition to standard antibiotic and other supportive therapy in the management of under-five children with severe pneumonia will significantly shorten the duration of severity of pneumonia and thereby reduce hospital stay and also reduce the risk of new episode of pneumonia.

Specific Objectives:

Objective: To assess the clinical benefit of oral vitamin D3 supplementation, in addition to standard antibiotic and other supportive therapy, in the management of hospitalised, under-five children with severe pneumonia.

Primary objective: To compare the duration of severe pneumonia of children in the two study groups receiving the standard therapy (appropriate antibiotic and other supportive therapy) with those receiving vitamin D supplementation in addition to the standard therapy.

Secondary objectives:

  • To compare the duration of hospitalization, fever, tachypnoea, chest in drawing, hypoxia, lethargy and inability to feed during hospital stay, in under-five children in the two study groups, as mentioned under the primary aim.
  • To compare the recurrence of new episode of pneumonia over the next 6 months after discharge from hospital in the two study groups.
  • To identify the optimum safety dose of vitamin D3 for different groups of under-five children.
  • In severe pneumonia patient who also have acute watery diarrhoea we will assess the indirect absorption of vitamin D by measuring serum vitamin D level and will also assess the clinical outcome in the subgroup.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 360 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Vitamin D Supplementation: Impact on Severe Pneumonia Among Under-five Children
Study Start Date : June 2014
Estimated Primary Completion Date : January 2020
Estimated Study Completion Date : January 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pneumonia Vitamin D

Arm Intervention/treatment
Active Comparator: Vitamin D3
Vitamin D3, Doses form: 20,000 IU vitamin D3 in children <6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days.
Drug: Vitamin D3
20,000 IU vitamin D3 in children <6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days
Other Name: Vigantol-oil

Placebo Comparator: Miglyol-oil
20,000 IU Miglyol-oil in children <6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days.
Drug: Placebo
20,000 IU Miglyol-oil in children <6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days
Other Name: Miglyol Oil




Primary Outcome Measures :
  1. Time taken for recovery from severe pneumonia [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. Duration of hospitalization [ Time Frame: 12 months ]
  2. Time taken for normalisation of temperature [ Time Frame: 12 months ]
  3. Time taken for normalisation of respiratory rate [ Time Frame: 12 months ]
  4. Time taken for recovery from chest in drawing [ Time Frame: 12 months ]
  5. Time taken for oxygen saturation to normalise [ Time Frame: 12 months ]
  6. Time taken for normalization of mental status [ Time Frame: 12 months ]
  7. Time taken for normalization of child feeding [ Time Frame: 12 months ]
  8. Proportion of study children who will develop new episode of pneumonia during the follow up period [ Time Frame: 12 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   3 Months to 59 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Children of either sex aged 3 - 59 months, with a clinical diagnosis of severe pneumonia with or without diarrhea.

Exclusion Criteria:

  1. Known case of hypercalcaemia or allergy to vitamin D, as determined by history or previous medical records.
  2. Congenital Heart disease, evidenced by clinical exam or past medical records.
  3. Renal or hepatic insufficiency, evidenced by clinical exams or past medical records.
  4. Known case of tuberculosis, evidenced by medical records
  5. Known case of asthma, evidenced by history and clinical exam findings.
  6. Critically ill children requiring ICU care, such as those with septic shock or cardiac arrest or apnoea.
  7. Received vitamin D or calcium supplementation within the last 4 weeks before current admission, as evidenced by history or medical prescription.
  8. Any children diagnosed as hypernatraemia during the main phase of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02185196


Contacts
Layout table for location contacts
Contact: Fahmida Chowdhury, MBBS, MPH 880 2 8860523 ext 2550 fahmida_chow@icddrb.org
Contact: Mohammod J Chisti, MBBS, MMed 880 2 8860523 ext 2334 chisti@icddrb.org

Locations
Layout table for location information
Bangladesh
Dhaka Hospital of the International Centre for Diarrhoeal Disease Research, Bangladesh Recruiting
Dhaka, Bangladesh, 1212
Contact: Fahmida Chowdhury, MBBS, MPH    880 2 8860523 ext 2550    fahmida_chow@icddrb.org   
Contact: Mohammod J Chisti, MBBS, MMed    880 2 8860523 ext 2334    chisti@icddrb.org   
Principal Investigator: Fahmida Chowdhury, MBBS, MPH         
Sponsors and Collaborators
International Centre for Diarrhoeal Disease Research, Bangladesh
Centers for Disease Control and Prevention
Investigators
Layout table for investigator information
Principal Investigator: Fahmida Chowdhury, MBBS, MPH International Centre for Diarrhoeal Disease Research, Bangladesh

Layout table for additonal information
Responsible Party: International Centre for Diarrhoeal Disease Research, Bangladesh
ClinicalTrials.gov Identifier: NCT02185196     History of Changes
Other Study ID Numbers: PR-13088
First Posted: July 9, 2014    Key Record Dates
Last Update Posted: March 5, 2019
Last Verified: February 2019

Keywords provided by International Centre for Diarrhoeal Disease Research, Bangladesh:
Vitamin D,
Severe pneumonia,
Under-five children,
Randomised
Controlled
Trial (RCT)
Morbidity

Additional relevant MeSH terms:
Layout table for MeSH terms
Vitamins
Vitamin D
Pneumonia
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Ergocalciferols
Cholecalciferol
Micronutrients
Nutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents
Calcium-Regulating Hormones and Agents